Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 ampli...

Descripción completa

Detalles Bibliográficos
Autores principales: Turkes, Fiona, Bryant, Annette, Begum, Ruwaida, Davidson, Michael, Kalaitzaki, Eleftheria, Aresu, Maria, Lazaro-Alcausi, Retchel, Bryant, Jane, Rana, Isma, Chua, Sue, Aronson, Lauren, Hulkki-Wilson, Sanna, Fribbens, Charlotte, Watkins, David, Rao, Sheela, Starling, Naureen, Cunningham, David, Chong, Irene Y., Chau, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029374/
https://www.ncbi.nlm.nih.gov/pubmed/35448150
http://dx.doi.org/10.3390/curroncol29040176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029374/
https://www.ncbi.nlm.nih.gov/pubmed/35448150
http://dx.doi.org/10.3390/curroncol29040176

Ejemplares similares